Portfolio contracting is quietly rewriting the rules of pharmaceutical market access. What began as a way to bundle a handful of related products has evolved into a defining access strategy that influences pricing, formulary positioning and competitive dynamics across therapeutic areas (TAs). Today, market success depends less on a single blockbuster drug than on how well manufacturers can leverage their portfolios at the negotiating table.
Before we dive into what’s happening in portfolio contracting today, let’s take a look at the most common contracting models pharma companies use to meet payer demands and optimize access:
- Traditional Rebate Contracts: Rebate-driven agreements offer discounts based on volume, formulary positioning, and/or market share guarantees. These contracts remain the backbone of U.S. market access, especially for high-volume TAs.
- Indication-Based Pricing: This model adjusts pricing based on the clinical value of a drug in specific indications. For example, an oncology therapy may carry different rebate levels depending on whether it is being used as a first- or second-line treatment.
- Outcomes-Based or Value-Based Agreements: These contracts link payment to real-world performance metrics, such as patient adherence, clinical outcomes, or hospitalization rates. If the drug fails to deliver agreed-upon results, the manufacturer provides additional rebates or refunds.
- Risk-Sharing Agreements: These agreements, which are common for high-cost or especially innovative therapies, distribute financial risk between manufacturers and payers. They often include caps on total spend and/or shared responsibility for treatment failures.
- Bundled Contracting: This strategy groups related products, such as multiple drugs within a therapeutic class or across a treatment pathway, under one negotiated price. It simplifies negotiations and can drive efficiencies for payers managing complex regimens.
- Portfolio Contracting: Portfolio contracting consolidates multiple products from the same manufacturer (often across TAs) into a single agreement. This model leverages scale and interdependence, creating deeper partnerships between manufacturers and payers.
Behind every high-level contracting strategy lies a complex web of legally binding pharmaceutical agreements. These contracts govern relationships between manufacturers, payers, CMOs, CDMOs, and distributors—each with its own compliance obligations, risk exposures, and regulatory requirements. The stakes are high: a single poorly drafted clause can delay a product launch, expose proprietary research, or even trigger regulatory violations that halt entire product lines.
Companies that excel in contract management gain real advantages: faster time-to-market, stronger partnerships, and better risk mitigation.
Evolution of Portfolio Contracting: Using Scale to Create Leverage
The last few years have seen portfolio contracting evolve from simple bundling into something far more complex, as the number of products included in these agreements has grown exponentially. What once might have been a two-drug bundle is now commonly a 10–20 product contract spanning several TAs and including both mature brands and newly launched products. Occasionally, a portfolio contract might also incorporate biosimilars or promising pipeline assets.
This portfolio expansion is driven by a simple reality: scale wins. Payers want consolidated discounts, and manufacturers want to protect their position in crowded categories. Larger bundles create tighter, more interdependent relationships. If a payer wants better pricing on a blockbuster product, the deal may also require favorable positioning for several other products in the manufacturer’s lineup.
The Market Power of Multi-Asset Deals
In one well-documented example, AbbVie used portfolio contracting for its immunology products, tying Humira access and rebates to positioning for its next-generation products (Skyrizi and Rinvoq) in payer negotiations. Independent analysis indicates Humira discounts/rebates reached approximately 60%–85% off the wholesale acquisition cost (WAC).
The company’s aggressive contracting helped entrench Humira coverage after its loss of exclusivity (LoE). Despite competition from multiple adalimumab biosimilars, Humira retained approximately 97% adalimumab volume share by the end of 2023, underscoring how portfolio-level terms protected market share while lowering net price.
Another example is GSK’s group-purchasing contracts, which cover its full, multi-asset pediatric/adult vaccine portfolio, including Shingrix (zoster), Boostrix (Tdap), Pediarix, Kinrix, Infanrix (DTaP combos), Hiberix (Hib), Menveo (MenACWY), Bexsero (Meningitis B), Priorix (MMR), Havrix/Engerix‑B/Twinrix (Hepatitis A/B).
Participants in GSK’s Premium Partner Program receive the lowest national pricing for all GSK vaccines by maintaining set market‑share compliance thresholds (e.g., ≥80% for pediatric/adult categories, ≥70% for meningococcal). In addition to 2% prompt-pay discounts, participants can save up to 33% per dose for these vaccines, demonstrating how portfolio compliance yields material unit‑cost reductions across the bundle.
Similarly, Pfizer also offers GPO/PBG contracting across its vaccine portfolio, which includes Prevnar 20, Abrysvo (RSV), Trumenba (MenB), Penbraya (MenABCWY) and Pfizer’s Comirnaty (COVID19). These single contracts span multiple adult/adolescent vaccine products and reflect tiered market share pricing (e.g., Tier 3 at ≥80% share across covered vaccines) as well as rebate ladders (e.g., a 3% rebate when portfolio thresholds are met). Limited-time 25% Trumenba and 11% Penbraya discounts were also offered to qualifying PBG members, quantifying how multi-asset commitments convert into lower net costs.
The GLP-1 Price Compression Playbook
One of the forces accelerating the use of portfolio contracting is the push for aggressive rebates. A real-world example of this dynamic can be seen playing out in the GLP-1 agonist market. In July 2025, Novo Nordisk secured preferred formulary status for its weight-loss drug Wegovy on CVS Caremark’s standard formularies—part of its broader GLP1 portfolio strategy that also includes its diabetes drugs, Ozempic and Rybelsus.
As part of portfolio-level contracting with major PBMs like CVS Caremark and Express Scripts, Novo saw the net price of Ozempic fall by approximately 40% from its list price, with the company reporting a 69% gross-to-net rebate adjustment across its GLP1 franchise. These rebates aren’t limited to loss-leader pricing; they extend throughout the company’s GLP1 portfolio, compressing net effective prices.
CVS publicly stated it negotiated a lower net price for Wegovy vs. Eli Lilly’s Zepbound for standard formularies (client optin), reducing both plan costs and members’ out-of-pocket costs. Simultaneously, Novo Nordisk also offered a $499/month cash price (vs. $1,349 list cost), which cut costs by approximately ~63% for selfpay patients.
In parallel, Cigna’s Express Scripts’ GLP1 programs, built via manufacturer agreements with Novo and Lilly, report $200M health plan savings since 2024. These programs began offering member copay caps (e.g., ≤$200/month) in mid-2025, showing portfolio agreements’ net spend compression across GLP1 products.
As payers and PBMs increasingly expect guarantees across the entire contract rather than product-specific negotiations, manufacturers are now measured by their ability to deliver financial value across multiple products, not just one. The result is a contracting environment in which net prices drop faster, and manufacturers compete not only via clinical differentiation, but also in terms of how much financial value they can generate across their product ecosystem.
PBMs and the Shift to Class-Level Negotiation
Another major trend is the growing influence of PBMs, who now use portfolio contracting to shape entire therapeutic classes at once. Their ability to consolidate products under one negotiation gives them significant leverage in dictating preferred formulary positions—sometimes creating exclusionary scenarios that affect competition across the market.
A vivid example is the adalimumab class in 2025. CVS Caremark, Express Scripts, and OptumRx jointly excluded Humira and nearly all branded biosimilars from their standard formularies, opting instead to promote their own private-label biosimilars under portfolio agreements.
By removing Humira and competing biosimilars from coverage, these PBMs forced manufacturers to offer deeper rebates to regain placement or accept exclusion entirely. In effect, bargaining turned from individual drugs to a restructured class-level negotiation, advantaging PBM-owned products and reshaping the competitive landscape.
Taken together, these trends show that portfolio contracting is no longer a supplemental negotiation strategy. It is becoming a foundational element of how access is won, maintained, and optimized in the U.S. pharmaceutical system.
Ripple Effects of Portfolio Contracting
Portfolio contracting impacts every group of healthcare stakeholders. For payers, the appeal is straightforward: predictable cost and simplified contracting. Larger bundled agreements give them greater budget control and allow them to negotiate significant savings. But the trade-off is reduced flexibility. Once a payer locks into a large portfolio contract, they cannot easily change their minds. Even if a competitor’s therapy is more clinically compelling, a decision to switch to that therapy may well incur hefty financial penalties.
For manufacturers, portfolio contracting involves both opportunity and risk. Larger companies with diverse portfolios gain a competitive edge, as they can use their product suite to secure preferred access for high-priority brands. But this dynamic also accelerates net price erosion, as manufacturers are expected to offer increasingly aggressive discounts to stay competitive. And as these agreements grow in scope and complexity, so do the operational and compliance risks for all parties involved. Portfolio contracts can go wrong in many ways:
- Timeline Slippage: Ambiguous contract terms—whether around manufacturing specifications or quality acceptance criteria—can force renegotiation mid-project.
- IP Erosion: Portfolio contracts that don’t clearly define background versus foreground intellectual property can inadvertently trigger disputes, compromising long-term patent positions.
- Compliance Exposure: All contracts must align with FDA requirements around facility inspections, supply chain traceability, and adverse event reporting. Vague compliance triggers create gray zones where neither party owns regulatory responsibility.
- Rebate and Pricing Risk: Poorly structured rebate clauses in commercialization agreements with distributors and payers can lead to Anti-Kickback Statute violations, which in turn can lead to civil penalties, mandatory refunds, and reputational damage.
Smaller or single-asset companies face the toughest challenges. Without a broad portfolio to negotiate with, they often struggle to meet the rebate expectations set by larger competitors. This can restrict formulary placement and limit patient access, ultimately pushing smaller companies toward partnerships and acquisitions simply to remain viable. In many ways, portfolio contracting amplifies the advantages of scale and deepens the structural challenges for emerging innovators.
Patients experience mixed outcomes. On one hand, payer savings may translate into lower premiums or broader drug affordability. On the other hand, the presence of large portfolio deals can restrict access to certain medicines, increase step therapy requirements, and/or force switches driven by financial incentives rather than clinical preference. While the system benefits from efficiencies, individual patients may have fewer choices.
Finally, PBMs emerge as some of the biggest beneficiaries. Portfolio contracting reinforces their central role in shaping drug access, as it expands their negotiating leverage and strengthens rebate-driven economics.
The Fine Line Between Leverage and Liability
Portfolio contracting has quickly become one of the most influential forces shaping U.S. market access. Its rise reflects broader trends, from payer consolidation to greater competition within TAs and the ongoing pressure to reduce drug spend. In this environment, portfolio contracts are poised to become even larger, more sophisticated, and more deeply integrated into pharma’s strategic planning.
Looking ahead, we can expect multi-year, multi-asset agreements to become more common, with value-based elements layered on top of traditional rebate structures. The inclusion of pipeline assets before launch may become routine.
As contracts grow, so too will regulatory interest, particularly around competition and patient access. To cite just one example, in May 2025, a federal jury found that Amgen violated antitrust laws by bundling its cholesterol drug Repatha with unrelated anti-inflammatory drugs Enbrel and Otezla to secure preferential formulary placement with major PBMs. This strategy practically excluded Regeneron’s competing product, Praluent, from formularies.
Ultimately, the jury awarded Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages, recognizing this as an unlawful attempt to suppress competition using exclusive portfolio terms. This case demonstrates how multi-asset rebate structures—a hallmark of portfolio contracting—can cross into antitrust territory when used to lock out competitors and undermine market competition.
As we’ve seen, portfolio contracting delivers efficiency and economic value, but it also raises important questions about competition, innovation, and equity of access. The industry’s main challenge will be ensuring that patients and smaller innovators are not left behind as payers, PBMs and manufacturers fight to maximize their profits.
